Merck is tackling its looming “Keytruda cliff” with a bold $10 billion acquisition of Verona Pharma. The deal brings Ohtuvayre, a first-in-class COPD drug, into Merck’s portfolio as it looks to ...

Merck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...

Pharmaceutical titan Merck & Co. Inc. has announced a landmark $10 billion acquisition of Verona Pharma plc, underscoring its ...

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

A key patent for Merck’s blockbuster drug Keytruda will expire in 2028. The cancer therapy brought the company $29.5 billion last year. Keytruda may also face “ price setting ” from the Inflation ...

Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...

Verona Pharma, a year after receiving regulatory approval for its landmark chronic obstructive pulmonary disease (COPD) treatment, is being acquired by pharmaceutical giant Merck in a deal worth about ...

Merck will fork out USD107 per American depository share in Verona, the Rahway, New Jersey-based pharmaceutical firm said. Each ADS represents eight Verona ordinary shares. The sum is a 23% premium to ...

Freshfields and Latham & Watkins are advising on the latest pharmaceutical mega-deal as U.S. pharmaceutical group Merck snaps up lung disease-focused biotech Verona Pharma. Merck, which is known as ...